Table 1.
Characteristics of selected patients with complete data. Statistics presented are median (IQR) or frequency (percent).
| Overall N=946 |
No Cancer (N=622; 66%) |
Low-Grade Cancer** (N=230; 24%) |
High-Grade Cancer*** (N=94; 10%) |
Other Races (N=846; 89%) |
Black, Non-Hispanic (N=100; 11%) |
|
|---|---|---|---|---|---|---|
| Age, years | 64 (60, 68) | 64 (60, 68) | 65 (61, 69) | 66 (61, 69) | 64 (60, 68) | 64 (60, 69) |
| Abnormal DRE | 141 (15%) | 67 (11%) | 45 (20%) | 29 (31%) | 123 (15%) | 18 (18%) |
| Race | ||||||
| White, non-Hispanic | 796 (84%) | 549 (88%) | 179 (78%) | 68 (72%) | 796 (94%) | 0 (0%) |
| Black, Non-Hispanic | 100 (11%) | 41 (6.6%) | 37 (16%) | 22 (23%) | 0 (0%) | 100 (100%) |
| Hispanic | 22 (2.3%) | 11 (1.8%) | 9 (3.9%) | 2 (2.1%) | 22 (2.6%) | 0 (0%) |
| Asian | 20 (2.1%) | 16 (2.6%) | 3 (1.3%) | 1 (1.1%) | 20 (2.4%) | 0 (0%) |
| Pacific Islander | 4 (0.4%) | 3 (0.5%) | 1 (0.4%) | 0 (0%) | 4 (0.5%) | 0 (0%) |
| American Indian | 2 (0.2%) | 1 (0.2%) | 1 (0.4%) | 0 (0%) | 2 (0.2%) | 0 (0%) |
| Unknown | 2 (0.2%) | 1 (0.2%) | 0 (0%) | 1 (1.1%) | 2 (0.2%) | 0 (0%) |
| Family History of PCa | 102 (11%) | 61 (10%) | 23 (10%) | 18 (19%) | 93 (11%) | 9 (9.0%) |
| Unknown | 8 (0.8%) | 3 (0.5%) | 3 (1.3%) | 2 (2.1%) | 7 (0.8%) | 1 (1.0%) |
| Total PSA, ng/mL | 5.8 (4.8, 7.6) | 5.6 (4.8, 7.0) | 6.0 (4.8, 8.2) | 8.0 (5.3, 17.4) | 5.8 (4.8, 7.5) | 5.9 (5.0, 8.5) |
| Free PSA, ng/mL | 1.1 (0.8, 1.5) | 1.2 (0.9, 1.6) | 1.0 (0.7, 1.4) | 1.1 (0.7, 1.8) | 1.1 (0.8, 1.6) | 1.0 (0.8, 1.4) |
| Intact PSA, ng/mL | 0.72 (0.54, 1.01) | 0.74 (0.57, 1.00) | 0.67 (0.49, 0.93) | 0.75 (0.50, 1.24) | 0.73 (0.55, 1.01) | 0.68 (0.50, 0.93) |
| hK2, ng/mL | 0.08 (0.05, 0.12) | 0.07 (0.05, 0.11) | 0.08 (0.05, 0.12) | 0.10 (0.06, 0.18) | 0.08 (0.05, 0.12) | 0.06 (0.04, 0.09) |
| MSP, ng/mL (N=938) | 21 (14, 30) | 23 (15, 32) | 18 (13, 27) | 16 (11, 25) | 22 (15, 31) | 15 (11, 22) |
| Risk of Cancer on Biopsy (%) | ||||||
| Age + PSA | 24 (22, 28) | 24 (22, 27) | 25 (22, 30) | 30 (23, 54) | 24 (22, 28) | 24 (22, 30) |
| Age + PSA + DRE | 19 (17, 26) | 19 (17, 22) | 21 (17, 39) | 31 (19, 51) | 19 (17, 25) | 20 (17, 35) |
| Age + Kallikrein Markers | 38 (30, 51) | 35 (26, 44) | 45 (37, 64) | 61 (44, 90) | 38 (30, 51) | 42 (32, 55) |
| Age + Kallikrein Markers + DRE | 35 (27, 50) | 31 (24, 41) | 42 (32, 64) | 62 (39, 89) | 34 (27, 50) | 38 (30, 55) |
| *PCPT risk calculator estimate | 30 (26, 35) | 29 (26, 33) | 32 (26, 39) | 38 (31, 49) | 29 (26, 33) | 40 (36, 48) |
| Risk of Gleason ≥7 Cancer on Biopsy (%) | ||||||
| Age + PSA | 8 (6, 10) | 7 (6, 9) | 8 (6, 12) | 10 (7, 24) | 8 (6, 10) | 8 (6, 12) |
| Age + PSA + DRE | 5 (4, 7) | 4 (3, 6) | 5 (4, 12) | 8 (4, 23) | 5 (3, 7) | 5 (4, 10) |
| Age + Kallikrein Markers | 7 (4, 16) | 6 (3, 10) | 12 (6, 28) | 25 (10, 59) | 7 (4, 16) | 10 (5, 21) |
| Age + Kallikrein Markers + DRE | 5 (3, 13) | 4 (2, 8) | 10 (4, 23) | 25 (7, 54) | 5 (3, 13) | 8 (3, 16) |
| PCPT risk calculator estimate* | 9 (7, 14) | 8 (7, 12) | 11 (7, 18) | 15 (10, 25) | 9 (7, 12) | 20 (17, 30) |
| Biopsy Gleason | ||||||
| No Cancer | 622 (66%) | 622 (100%) | 0 (0%) | 0 (0%) | 581 (69%) | 41 (41%) |
| Low-Grade Cancer** | 230 (24%) | 0 (0%) | 230 (100%) | 0 (0%) | 193 (23%) | 37 (37%) |
| Gleason Score 7 (GGG 2 or 3) | 72 (7.6%) | 0 (0%) | 0 (0%) | 72 (77%) | 54 (6.4%) | 18 (18%) |
| Gleason Score ≥8 (GGG 4 or 5) | 22 (2.3%) | 0 (0%) | 0 (0%) | 22 (23%) | 18 (2.1%) | 4 (4.0%) |
DRE = digital rectal examination, PCa = prostate cancer, PSA = prostate-specific antigen, hK2 = human kallikrein-2, MSP = microseminoprotein-beta, PCPT = Prostate Cancer Prevention Trial, GGG = Gleason Grade Group
*
PCPT risk calculator estimate = prespecified PCPT risk calculator version 2.0 model
**
Low-grade Cancer includes Gleason score 6 (Gleason Grade Group 1)
***
High-grade Cancer includes Gleason score ≥7 (Gleason Grade Group ≥2)